Aims and Scope
Molecular Oncology is an Open Access international journal that highlights new discoveries, approaches, as well as technical developments, in basic, clinical and discovery-driven translational cancer research.
The emphasis is on work that significantly advances our understanding of disease processes leading to human tumour development and/or establishes novel concepts of clear clinical significance in diagnosis, prognosis and prevention strategies for cancer patients.
Topics include, but are not limited to:
- Key biological processes such as cell cycle; DNA repair; apoptosis; invasion and metastasis; angiogenesis and lymphangiogenesis; cell signalling and interactive networks; immune response.
- Emerging technologies (genomics, proteomics, functional genomics, metabolomics, tissue arrays, imaging), and model systems.
- Biomarkers: diagnosis, prognosis, stratification and efficacy.
- Cancer genetics, epigenetics, and genomic instability.
- Minimal residual disease, pre-malignant lesions.
- Cancer micro-environment.
- Molecular pathology.
- Tumour immunology.
- Translational research.
- Cancer therapy (target discovery, drug design, immunotherapy, combination therapies, resistance, and individualised treatment).
- Chemotherapy, radiotherapy and surgery.
- Clinical pharmacology.
- Clinical trials, integration of basic science into cancer clinical trials.
- Molecular epidemiology.
- Research articles
- Reviews (these are invited only)
- Science policy articles
From the 1st of August 2016, manuscripts can be submitted to Molecular Oncology at: https://mc.manuscriptcentral.com/molonc
Journal Special Features
From January 1, 2017 Molecular Oncology is published by FEBS Press and Wiley
Molecular Oncology has become fully Open Access, allowing everyone to read the journal irrespective of speciality, host institution or location. All articles are published under the Creative Commons Attribution License (CC BY) to meet funders’ requirements worldwide.
- 2016 2-Year Impact Factor: 5.314
- 2016 5-Year Impact Factor: 5.957
- 2016 CiteScore: 5.25
Editor-in-Chief Julio Celis
Managing Editor Jose Moreira